Swedish Orphan Biovitrum AB (publ) is committed to upholding a strong set of values and corporate philosophy. The company prioritizes patient well-being and aims to make a positive impact on the lives of individuals affected by rare diseases. Swedish Orphan Biovitrum AB (publ) embraces an open and collaborative approach, fostering innovation and learning within the healthcare industry. With a focus on delivering high-quality therapies, the company strives to be a trusted partner for patients, healthcare providers, and society as a whole. Swedish Orphan Biovitrum AB (publ) consistently demonstrates its dedication to integrity, excellence, and sustainable practices.

Swedish Orphan Biovitrum AB (publ) primarily operates in various countries and regions worldwide. The company has a global presence, with a significant focus on Europe. It has established a strong presence in Nordic countries such as Sweden, Norway, Denmark, and Finland. Additionally, Swedish Orphan Biovitrum AB (publ) has expanded its operations to other European countries, including the United Kingdom, Germany, France, Italy, Spain, and Switzerland. It also has a growing presence in North America, particularly in the United States and Canada. Moreover, the company is actively exploring opportunities in emerging markets to further expand its geographical footprint.

Swedish Orphan Biovitrum AB has accomplished several significant milestones. Notably, the company successfully launched Elocta, a treatment for hemophilia, in multiple countries. It gained regulatory approvals for Alprolix, a therapy for hemophilia B, and Orfadin, a medication for the treatment of hereditary tyrosinemia type 1. Swedish Orphan Biovitrum AB (publ) also established strategic partnerships, including collaborations with Bioverativ, Biogen, and Novimmune. Moreover, the company expanded its product pipeline through acquisitions, such as Dova Pharmaceuticals and Emalex Biosciences. These achievements solidify Swedish Orphan Biovitrum AB's position as a leader in providing innovative treatments for rare diseases.

Swedish Orphan Biovitrum AB (publ) is a multinational pharmaceutical company focused on rare diseases and specialty care. Established in 2001, it has a rich history of developing innovative therapies to address unmet medical needs. The company operates across several therapeutic areas, including hematology, immunology, and genetic diseases. Swedish Orphan Biovitrum AB (publ) collaborates with partners worldwide to advance their extensive product portfolio, leveraging their expertise to improve patients' lives. With a strong commitment to research and development, the company continues to make significant contributions to the field of healthcare. Swedish Orphan Biovitrum AB (publ) is dedicated to driving advancements in rare diseases and expanding access to life-changing treatments.

The main competitors of Swedish Orphan Biovitrum AB (publ) in the market include companies such as Novartis AG, Roche Holding AG, Biogen Inc., and Takeda Pharmaceutical Company Limited. These pharmaceutical companies operate in a similar market segment and represent strong competition for Swedish Orphan Biovitrum AB (publ).

Swedish Orphan Biovitrum AB (publ) is primarily active in the pharmaceutical industry.

The business model of Swedish Orphan Biovitrum AB (publ) focuses on developing and commercializing innovative treatments for rare diseases. The company specializes in providing therapies that address unmet medical needs, primarily within the areas of hematology, immunology, and genetic diseases. Swedish Orphan Biovitrum AB (publ) engages in extensive research and development efforts to create effective and safe drugs for patients, collaborating with various partners in the healthcare industry. By prioritizing rare diseases and leveraging its expertise, Swedish Orphan Biovitrum AB (publ) aims to improve the lives of patients worldwide through its specialized treatments.

The Swedish Orphan Biovitrum AB (publ) P/E ratio is 21.03.

The Swedish Orphan Biovitrum AB (publ) P/S ratio is 3.62.

The Quality Investing for Swedish Orphan Biovitrum AB (publ) is 5/10.

The expected Swedish Orphan Biovitrum AB (publ) revenue is 28.65 B SEK.

The expected Swedish Orphan Biovitrum AB (publ) profit is 4.93 B SEK.

Swedish Orphan Biovitrum AB is a biopharmaceutical company specializing in rare diseases and specialty medicines. It is divided into three main business areas: coagulation disorders, immunology, and genetics. The company develops, manufactures, markets, and distributes medications for these rare diseases. The coagulation disorders division focuses on products for the treatment of hemophilia, thrombosis prevention, and bleeding. The immunology division focuses on products for the treatment of rare diseases such as hereditary angioedema and primary immune thrombocytopenia. The genetics division focuses on products for the treatment of rare genetic diseases such as Gaucher's disease, Fabry disease, and Pompe disease. The company distributes its products globally and works closely with patient organizations and healthcare providers to ensure access to medication and information for patients with rare diseases. The company also invests heavily in research and development for new therapies and diagnostic procedures for rare diseases. The business model of Swedish Orphan Biovitrum is based on the production and marketing of specialty medicines for the treatment of rare diseases. It focuses on niche markets where it has strong expertise and collaborates with patient organizations and healthcare providers to meet patient needs. The company achieves high value creation and builds a differentiated competitive advantage by focusing on rare diseases.

Swedish Orphan Biovitrum AB (publ) pays a dividend of 0 SEK distributed over payouts per year.

The dividend cannot currently be calculated for Swedish Orphan Biovitrum AB (publ) or the company does not pay out a dividend.

The ISIN of Swedish Orphan Biovitrum AB (publ) is SE0000872095.

The WKN of Swedish Orphan Biovitrum AB (publ) is A0LA5K.

The ticker of Swedish Orphan Biovitrum AB (publ) is SOBI.ST.

Over the past 12 months, Swedish Orphan Biovitrum AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Swedish Orphan Biovitrum AB (publ) is expected to pay a dividend of 0 SEK.

The current dividend yield of Swedish Orphan Biovitrum AB (publ) is .

Swedish Orphan Biovitrum AB (publ) pays a quarterly dividend. This is distributed in the months of .

Swedish Orphan Biovitrum AB (publ) paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

Swedish Orphan Biovitrum AB (publ) is assigned to the 'Health' sector.

To receive the latest dividend of Swedish Orphan Biovitrum AB (publ) from 10/12/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/12/2025.

The last dividend was paid out on 10/12/2025.

In the year 2024, Swedish Orphan Biovitrum AB (publ) distributed 0 SEK as dividends.

The dividends of Swedish Orphan Biovitrum AB (publ) are distributed in SEK.